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Abstract
: Our aim was to compare a less intensive but longer pulmonaryAim
rehabilitation programme (PRP) against a more intensive but shorter PRP.
: We carried out an observational, cohort study in a real-life clinicalMethods
setting in patients primarily with chronic obstructive pulmonary disease
(COPD). We compared standard outcomes in patients who were receiving 18
sessions of PRP delivered twice weekly over 9 weeks (Group 1) against similar
patients receiving an identical PRP delivered three times weekly over 6 weeks
(Group 2). Outcome measures were the St. George’s Respiratory
Questionnaire (SGRQ), the Incremental Shuttle Walk Test (ISWT) and the
number of hospital bed-days pre- and post-PRP.
: Both groups showed statistically significant and clinically importantResults
improvements post-PRP. The largest effects were seen immediately post-PRP
and waned over the following 12 months. Group 1 showed a larger
improvement in ISWT immediately post-PRP (Group 1, +92 m Group 2versus 
+64 m ( =0.001), but there were no differences between groups at 6 ( =0.67)p p
or 12 months (p=0.96). There were no differences in SGRQ between groups
immediately post-PRP ( =0.09) or at 12 months ( =0.78). There were nop p
differences between groups in the number of hospital days 12 months prior to
PRP versus 12 months post-PRP ( =0.18).p
: Twice weekly outpatient, multidisciplinary PRP over 9 weeks is asConclusion
effective as three times weekly PRP over 6 weeks.
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Introduction
Randomised trials have demonstrated that Pulmonary Rehabilita-
tion Programs (PRPs) for patients with chronic obstructive pulmo-
nary disease (COPD) can improve dyspnoea, exercise tolerance, 
health-related quality of life (QoL), and reduce the number of hos-
pital days and the utilization of healthcare resources. Research has 
demonstrated that PRPs are cost-effective and as such they are now 
recommended to all patients, who remain breathless despite opti-
mal bronchodilators, irrespective of severity and age1–4. In addition, 
evidence is mounting for the efficacy of PRPs in patients with non-
COPD causes of pulmonary impairment5.
As evidence accumulates, there are now specific recommendations 
for PRPs regarding patient selection, timing (in relation to exac-
erbations etc.), intensity and type of exercises, educational, psy-
chological and behavioural components, oxygen supplementation, 
what outcomes to measure and total duration3–7. However, there still 
remain unanswered questions including what are the best sites for 
delivery of a PRP, whether nutritional supplementation should be 
offered during PRP, what are optimal target populations and what 
post-rehabilitation maintenance strategies reduce the declines seen 
in nearly all settings7–9. Other important concerns relate to variable 
attendance and high drop-out rates in PRPs10,11. We have shown 
that certain factors at enrolment can predict later poor attendance 
at PRP10, but interventions to improve the completion rates of these 
more vulnerable groups are still being researched.
Despite a general improvement in the provision of PRPs since 
2003, there remains poor access to PRPs in some parts of the United 
Kingdom (UK). Those hospitals/community services that provide 
PRPs describe variable content and staffing and many report long 
waiting times12. However, there is less evidence for other chronic 
care programs for COPD such as Home Exercise or Hospital at 
Home13. In the current financial climate, reduced resources are 
available for developing novel strategies for COPD care so optimi-
sation and evolution of those existing services with a good evidence 
base should be explored.
Comparable efficacy from a longer but less intensive PRPs may 
allow more flexible working for staff (e.g. part-time) to deliver an 
effective PRP or allow existing full-time staff to offer more than 
one PRP simultaneously, for example on different weekdays in dif-
ferent sites to improve local access, increase throughput and reduce 
waiting times.
We present immediate and one year outcomes from a real-life clini-
cal setting comparing the delivery of identical 18-session PRPs, 
delivered by the same staff, simultaneously across two similar 
nearby hospitals. This PRP occurred three times per week over 
6 weeks or twice per week over 9 weeks within the same Health 
Board (group of hospitals).
Methods
We sought advice regarding whether ethical approval was required 
for the study. As this was a retrospective review of prospectively 
collected routine clinical data (service evaluation) ethics approval 
was not deemed necessary.
Patients were referred from primary or secondary care onto the 
PRP. A respiratory physician first checked and optimised treat-
ment and excluded those with dementia, unstable cardiac disease 
or unwillingness to commit to a program. We include data on all 
those who attended for pre-PRP assessment (consisting of a brief 
interview and description of the service) by our physiotherapist and 
occupational therapist.
Our PRP was closely developed from our mentor’s model that has 
a strong evidence base14,15. It consists of 18 sessions of outpatient 
multidisciplinary input from occupational therapists, physiothera-
pists (including a teacher of the Chronic Respiratory Disease 
Exercise instructor course, endorsed by Loughborough College and 
British Lung Foundation), dietetics staff, pharmacist, physicians, 
specialist respiratory nurses and a smoking cessation counsellor.
Each session lasted for approximately 2.5 hours starting with super-
vised, individual exercise prescription of lower extremity training 
(treadmill, step-ups) and upper extremity training (resistance bands 
and loose weights). This was followed by group educational activi-
ties addressing the causes and types of lung disease and psycho-
logical aspects of chronic disability. Individual goal setting, dietary 
interventions, physiotherapy and occupational therapy were also 
included with voluntary sessions of relaxation classes and breath-
ing retraining exercises where attention was paid to emotional and 
social as well as physical aspects of health. Very occasional provi-
sion was made for additional sessions following non-attendance or 
further deterioration e.g. two people were awaiting lung transplant.
Completers (defined as attending 12 or more from 18 sessions) 
were referred to a follow-up component of self-exercise free classes 
in gyms in local leisure centres. All participants were given a pack 
at enrolment emphasising regular exercise with personalised goals 
and information on COPD.
In our health board, we split our daily PRP over 5 days per week 
between two similar medium-sized hospitals (25 miles apart). One 
hospital, which serves an urban (ex-industrial) and semi-rural area, 
offered 18 sessions of PRP, three times weekly over 6 weeks (Mon-
day, Wednesday and Friday afternoons). The other hospital is based 
in market town serving a rural area; because of greater distances 
involved in travelling, it offered the identical PRP of 18 sessions 
but twice weekly over 9 weeks (Tuesday and Thursday afternoons). 
Both groups were encouraged to exercise at home and the patients 
receiving PRP twice weekly were asked to try an independent home 
exercise session on a third day each week, replicating the hospital 
exercises where possible. The content, staff members and time of 
day of the PRPs were identical. This was thus a naturalised nested, 
cohort study allowing a unique opportunity to compare two intensi-
ties of identical PRPs.
Subjects completed the SGRQ and Medical Research Council 
(MRC) dyspnoea scores (under supervision) before completing a 
baseline ISWT16 1 week prior to PRP. They completed the same 
QoL survey and the ISWT immediately post-PRP and then 6 and 
12 months later.
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Information regarding admissions was extracted from our hospital 
database and all data for publication has all been anonymised and 
approved by our Hospital Caldicott Guardian for export.
We used the statistical package for social sciences (SPSS), version 
21.0 (Chicago, Illinois). Data are expressed by means and standard 
deviations. Analysis of the results was by intention to treat (ITT). 
Between-group comparisons were carried out at each time point 
using unpaired samples t-tests, Mann-Whitney and Chi square. 
Within-group changes were assessed using paired samples t-tests 
and Wilcoxon rank tests. A p value of less than 0.05 was deemed 
statistically significant.
Results
a) The overall PRP results are described below:
244 patients entered PRP between March 2006 and September 
2008.
74% had purely COPD and 26% were disabled by lung disease 
primarily from other conditions including idiopathic pulmonary 
fibrosis (5%), bronchiectasis (11%), chronic asthma (7%), kyphosco-
liosis (1%) or other respiratory conditions (2%).
48% were male; overall the subjects had a mean age of 66.0±9.5 
years, and the mean forced expiratory volume in 1 second (FEV1) 
recorded from clinics prior to PRP, was 46±19% predicted.
The median (inter-quartile range) attendance was 13 (7, 16) from a 
maximum 18 sessions with 56% of patients completing 12 or more 
sessions.
Complete data on ISWT and QoL scores were available for 223 
people at baseline, 161 people post-PRP, 89 people at 6 months and 
53 people at 12 months.
The mean ISWT improved from 155±123 metres immediately pre-
PRP to 241±152 metres immediately post-PRP (p<0.001). This had 
fallen back slightly to 199±146 metres at 6 months (p<0.01 from 
baseline) and 168±170 metres at 12 months (p<0.05 from baseline).
The total SGRQ at baseline was 63.1±15.6, immediately post-PRP 
was 53.6±15.5 (p<0.001), at 6 months was 56.7±15.6 (p<0.001 
from baseline) at 12 months was 56.6±16.8 (p=0.07 from baseline).
The mean number of admissions 6 months prior to PRP was 
0.69±1.20 and in the 6 months following PRP was 0.39±0.94 
(p<0.001).
The mean number of days spent in hospital 6 months prior to PRP 
was 5.54±15.20 and in the 6 months following PRP was 2.70±8.11 
(p<0.001).
The mean number of admissions 12 months prior to PRP was 
1.05±1.60 and in the 12 months following PRP was 1.11±1.55 
(p=0.66).
The mean number of days spent in hospital 12 months prior to 
PRP was 7.35±16.77 and in the 12 months following PRP was 
8.63±19.23 (p=0.55).
b) Comparison between twice weekly versus three times weekly 
PRPs:
Table 1 describes the patients enrolled in the two separate PRPs 
at baseline. Apart from the ISWT, the two groups were similar in 
baseline characteristics.
Table 2 compares the changes from baseline to 6 and 12 months in 
both groups. There was a significant difference in the ISWT post-
PRP between the two groups but this was no longer apparent 6 or 12 
Table 1. Baseline characteristics of the patients attending each of the PRP 
sessions.
Hospital 1 (2 sessions 
per week) n=95




Age (years) 65.9±8.6 66.1±10.1
FEV1% pred 43±19 47±19
PRP sessions completed 11.2±6.4 11.6±5.8
Shuttle walk (m)* 186±133 135±112
Total SGRQ* 59.0±15.8 65.6±15.0
MRC dyspnoea scale 3.5±1.0 3.6±0.8
Days in hospital previous 
6 months 3.4±6.9 6.9±18.6
Days in hospital previous 
12 months 4.2±6.9 9.4±20.6
* p<0.05
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months post-PRP. This may be due to the significantly lower mean 
ISWT at baseline. There was a significant difference in the SGRQ 
scores post-PRP, but again this was not apparent at the later time 
points. There were no differences in the number of hospital days 
pre- and post-PRP between the two PRP groups.





This is the first study to report immediate and medium term out-
comes from two PRPs that were identical apart from the intensity 
of sessions. We found statistically significant and clinically impor-
tant improvements in ISWT and QoL immediately following both 
PRPs. These effects were waning but still apparent at 6 months. 
At 12 months there was an overall mean change of +13 metres in 
ISWT which, although statistically significant, is unlikely to be 
clinically important. The mean improvement in total SGRQ of 
around 7 units from baseline to 12 months, however, is still likely 
to be clinically important but did not reach statistical significance 
(p=0.07) and could have occurred through chance and survivor 
selection bias. There were reductions in the number of hospital 
admissions and number of days spent in hospital within both PRP 
groups and as a population overall, comparing the 6-month periods 
immediately before and after PRP, but no differences in the num-
ber of admissions and days in hospital at 12 months. In Griffiths’ 
landmark randomized controlled trial of a PRP with identical staff-
ing and content to ours, occurring three times weekly, there were 
similar improvements in SGRQ, ISWT and days in hospital (but 
not number of admissions) in those receiving PRP in addition to 
usual care14. These differences remained statistically different from 
a control group of people with similar COPD, at 12 months could 
be at least partly due to deterioration due to progressive COPD 
in the usual care group. We had no such ‘usual care’ group like 
Griffith’s group in his randomised controlled trial as not offer-
ing PRP’s would now be considered unethical. We compared our 
12-month outcomes within the same patients one year before, when 
they were younger and so their disease (and co-morbidity) was 
probably less advanced. Showing equivalent ISWT and health care 
utilisation over 1 year, at least shows a halting or stabilising of what 
has been traditionally labelled a ‘chronic progressive irreversible 
lung disease’ (goldcopd.org).
Our patient outcomes are similar to others (that came mainly from 
more established academic units)6,8,14,15,18 and this helps to validate 
our PRP by confirming benefits within an everyday clinical setting. 
This indicates that PRPs should be offered in a non-teaching group 
of hospitals. Our outcomes are also comparable or superior to other 
‘before-and-after’ studies in real-life service evaluations. For exam-
ple, O’Neill et al. reported improvements in mean ISWT of around 
23 metres immediately after completing a supervised, outpatient 
PRP over 6 weeks, but their PRP was only once weekly and only 
reported on 74 patients. Like us, their effects were still apparent but 
waning at 6 months but not reported at 12 months16.
The comparison between twice versus three times weekly PRPs 
revealed subtle changes. Interestingly, the less intensive, twice 
weekly group showed greater improvement in ISWT immediately 
post-PRP but the groups were not completely matched and this 
could be confounded by their greater exercise tolerance (higher 
ISWT) and better disease specific quality of life (lower SGRQ) at 
baseline. It is easy to suggest that the patients could exercise more 
at home between supervised hospital sessions so could achieve 
bigger overall gains in exercise performance, during their hospital 
attendances.
We had a mixture of people with lung disease and some with very 
severe airflow obstruction. Garrod et al. reported less favourable 
outcomes in ISWT for those with more severe disease (higher 
MRC dyspnoea scores), possibly because they attended PRP less 
frequently17. Our actual percentage change in ISWT from baseline 
Table 2. Comparison between outcomes in patients of the two PRP groups.
Hospital 1 (2 sessions 
per week) n=95
Hospital 2 (3 sessions 
per week) n=149 p-value
ISWT (m) post-PRP +92±74 +64±61 0.003
ISWT 6 months post-PRP +49±62 +45±87 0.67
ISWT 12 months post-PRP +8±27 +35±90 0.86
SGRQ post-PRP -5.6±11.8 -9.7±12.6 0.09
SGRQ 6 months post-PRP +0.1±13.2 -5.6±11.4 0.02
SGRQ 12 months post-PRP -3.7±13.3 -5.4±13.8 0.78
Days in hospital 6 months pre- versus 
6 months post-PRP -1.8±8.7 -5.7±23.9 0.67
Days in hospital 12 months pre- versus 
12 months post-PRP +3.7±14.5 -3.9±23.1 0.18
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was similar in the twice versus three times weekly PRP (6% versus 
7% improvement); moreover any early differences in ISWT between 
the twice versus three times weekly PRP groups were no longer 
apparent at 6 and 12 months.
Both groups had statistically significant and clinically important 
improvements in SGRQ immediately following PRP. Those receiv-
ing three times weekly PRP showed a larger change and this dif-
ference could be clinically important as a difference of 4 units in 
the SGRQ is traditionally deemed a clinically important outcome 
(Meguro 2006). There was a -9.7 change in three times weekly vs -5.6 
change in twice weekly so difference of 4.1 units between groups in 
their changes), although this clinically important change could still 
have occurred through chance (p=0.09). This greater early improve-
ment in QoL may be explained by the more intensive program but 
is confounded by the poorer QoL at baseline and is easily explained 
by statistical chance. The difference between groups in SGRQ at 
6 months (+0.1 from baseline in twice weekly versus -5.6 in the 
three times weekly) did suggest ongoing benefit only for the latter 
group versus an earlier return to baseline in the less intensive group. 
However, there were no differences between the two groups in any 
outcome at 12 months, and the difference in SGRQ at 6 months 
could be due to a statistical aberration (multiple comparisons) as 
this single reading went against all the other outcome trends.
Few others have compared more versus less frequent sessions in 
PRPs. Green et al. suggested initially that a 7 week course provided 
greater early benefits in health status than a similarly intensive but 
shorter 4 week course18. The same group then later reported that a 4 
week supervised PRP with similar educational content is equivalent 
to a 7 week supervised PRP in clinical outcomes both at 7 weeks 
and 6 months19.
We have previously reported that a longer PRP was associated with 
lower attendance10. Possible reasons could be that participants notice 
less incremental change and that there is more time for intercurrent 
illness/exacerbations or other activities to interfere with attendance. 
This was based on an internal study comparing three sessions over 
6 weeks versus one session over 18 weeks and was entered along 
with other attendance predictors in a multi-regression model. The 
original randomised controlled trial was never completed due to the 
death of the lead investigator. Marciniuk et al. suggested the 
opposite, i.e. that longer PRPs (beyond 6 to 8 weeks) better main-
tain health gains7 and Rossi et al. reported that a ten session PRP 
provides only limited clinically significant improvements when 
compared with a longer 20-session course in outpatients with mild-
to-moderate severity COPD20.
Our study has some weaknesses; this is not a randomised controlled 
trial and real world observational studies may be confounded by 
non-randomisation of participants. Our two PRP cohorts were not 
exactly matched; those enrolled in the three times weekly PRP had 
a statistically significant higher SGRQ and lower ISWT at base-
line suggesting more respiratory impairment, despite similar age, 
FEV1 gender and disease mix. Those in the three times weekly 
PRP tended to have a higher number of admissions and days in 
hospital before PRP although this could have occurred through 
chance (p>0.05). The hospital offering the three times weekly PRP 
serves a larger urban population with higher levels of smoking, 
more ex-industrial workers and deprivation and so higher COPD 
prevalence and likely more co-morbidities. Despite a faster turno-
ver and a higher throughput of patients, it has longer waiting times 
for PRP suggesting a greater local need. Although the absolute 
improvement in ISWT (metres) was bigger in the hospital offering 
PRP twice per week, this could be influenced by their greater exer-
cise capacity to begin with and the relative (percentage) improve-
ment from baseline (as opposed to actual metres); immediately 
post-PRP was similar in both groups (p=0.39).
The study could be open to selection/reporting bias as there was 
incomplete data especially at 12 months with only around 20% of 
patients returning to hospital for completion of SGRQs and ISWTs. 
The lower numbers with available data at 12 months also contrib-
uted to a large data spread, especially for ISWT. These re-attenders 
could be those who obtained the biggest gains and wanted to sup-
port the service - or alternatively they could consist predominantly 
those asking for more help because of limited improvements. How-
ever, our attrition rate over 12 months is typical of others, and as 
a group, these long-term attenders have similar characteristics to 
others14. There were no differences in baseline factors between 
those who completed data collection and those who did not.
Our study has many strengths. It provides a unique opportunity 
to describe a real-life service but taking advantage of a real-time 
‘natural experiment’ where two PRPs are identical in staffing and 
process apart from the intensity. Both services are well-described 
and follow evidence-based guidelines. The size of our study com-
pares well with others and our patient selection, content, delivery 
and staffing is typical of many UK hospitals outside of specialist 
centres. Our immediate and short-term outcomes of PRP are com-
patible with others and offer some insights into more longitudinal 
(12 month) data, albeit with some caveats. Real-life observational 
studies can sometimes yield valuable insights. Atypical staff or 
patient behaviour does not limit them to the same extent as a ran-
domised controlled trial, nor are they restricted by strict age and 
severity inclusion criteria, or the exclusion of patients with co-morbid 
illnesses21. Real-life clinical studies are more generisable than ran-
domised trials from specialist centres or those designed/funded by 
institutions with a financial interest in outcomes.
Our data suggest that offering a longer twice weekly PRP instead 
of a more intensive three times-weekly PRP leads to similar attend-
ance and has not compromised outcomes. Longer PRPs may pro-
vide more opportunities for continuing exercise. Certainly continuing 
exercise after PRP is now acknowledged to be a vital component 
on its own22. A twice weekly PRP would allow participants to have 
more time during the week to start exercising independently (e.g. 
attend leisure centres) and to identify early problems/build confi-
dence during their hospital PRP, well before they are discharged 
from the scheme. This could help address some of the remaining 
issues with continuing exercise and slowing deterioration after PRP. 
Importantly, slightly less intensive PRPs allow flexibility in service 
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provision, for example, re-allocating staff from the third PRP day-
of-the-week (e.g. Wednesdays) to instead promote sustainable exer-
cise schemes for previous completers or working in the community 
for those unable to attend the hospital/day care unit7,17,23. Alter-
natively, twice weekly PRP would allow existing staff working a 
typical 5 day week, to run two PRPs simultaneously per week with 
one day per week allocated for reviews/baseline assessments. With 
the increasing pressure on clinical resources, a twice weekly PRP 
allows less than 50% whole time equivalent staff to run a single 
PRP over 2 days per week without compromising standards. We 
now run both PRPs 2 days a week allowing part-time working and 
the same staff to contribute to other respiratory services within the 
existing team, whilst monitoring our waiting lists.
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The subject (impact of the frequency of supervised training) is clinical relevant and not sufficiently
evaluated. They have used a real-life study comparing two hospitals with identical rehabilitation except for
the number of supervised trainings – twice or three times a week.  They have discussed the limitations
and strength of this design. They have included enough patients to test for relevant differences between
these two programmes. The patients have been adequately characterised at baseline, and the authors
have used relevant outcomes.
They write that median attendance was 13 (maximum 18 sessions), but I cannot find data on difference
between the two programmes. Information on home training is also welcomed.
They have used proper statistical analyses. It is well written, and data are discussed sensibly in context
with other studies. 
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
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